Augustine Asset Management Inc. Has $587,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Augustine Asset Management Inc. cut its holdings in Johnson & Johnson (NYSE:JNJ) by 1.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,747 shares of the company’s stock after selling 68 shares during the quarter. Augustine Asset Management Inc.’s holdings in Johnson & Johnson were worth $587,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $37,000. Tower View Wealth Management LLC boosted its stake in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC boosted its stake in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson during the second quarter valued at about $48,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently commented on JNJ shares. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Raymond James lifted their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $177.31.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $152.31 on Wednesday. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market capitalization of $367.03 billion, a price-to-earnings ratio of 11.03, a price-to-earnings-growth ratio of 2.56 and a beta of 0.53. The business has a 50-day moving average of $157.79 and a 200-day moving average of $156.18.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.35 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.